Determination of Regulatory Review Period for Purposes of Patent Extension; ABRYSVO

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for ABRYSVO, a human biological product, and is publishing this notice as required by law. The FDA made this determination due to a patent extension application submitted to the US Patent and Trademark Office (USPTO).